Abstract
Synthetic cannabinoids (SCs), such as K2 or spice, are potent, intoxicating, laboratory-produced compounds designed to mimic Δ9-tetrahydrocannabinol (Δ9-THC). Some SCs are full agonists that bind to cannabinoid receptors in the endocannabinoid system with significantly higher affinity than Δ9-THC, often causing more intense and unpredictable effects, including cardiovascular, respiratory, and neuropsychiatric complications. Due to their modifiable chemical structures, new SC variants are commonly created and can evade detection on standard toxicology screens, complicating diagnosis and treatment. A 43-year-old male with schizoaffective disorder and polysubstance dependence presented with mental status changes and respiratory depression following suspected SC use with K2. Symptoms improved with intranasal naloxone despite negative toxicology screens for opioids and known SCs. The patient later admitted to ongoing K2 use. A unit search revealed leafy substances though confirmatory testing was negative. This case raises important considerations about the limitations of routine toxicology screening and the risk of SC adulteration with opioids or other undetected substances. The patient's repeated clinical improvement following naloxone suggests either opioid contamination or functional interactions between cannabinoid and opioid receptors. Preclinical evidence supports the existence of CB1-opioid receptor cross talk, offering a possible explanation for naloxone's effectiveness in SC-related toxicity. Clinicians should consider naloxone in cases of suspected SC overdose even without confirmed opioid exposure. Naloxone's safety profile and rapid onset make it an additional tool in managing undifferentiated overdose presentations. Further research is needed to delineate the mechanism behind naloxone's potential effectiveness in SC-related toxicity.